Creative Planning’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History

Creative Planning’s Portfolio UBIO Stock Details UBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-200	Closed	-$5K	–	4601
2016 Q1	$5K	Buy	+200	New	+$5.52K	﹤0.01%	3636

Other funds holding UBIO

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Creative Planning's UBIO Position: Q2 2016 in Review

Creative Planning sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q2 2016, closing a stake of 200 shares — an estimated $5K sold.

Creative Planning first reported a position in UBIO in Q1 2016 and held it in 1 quarter. The position peaked at $5K in Q1 2016. 7 funds tracked by Wall St. Rank hold UBIO as of Q2 2016.

Creative Planning reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q2 2016 after selling out during the quarter.
Creative Planning sold 200 Proshares UltraPro NASDAQ Biotechnology shares in Q2 2016, an estimated $5K.
Creative Planning first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q1 2016 and held it in 1 quarter.
Creative Planning's Proshares UltraPro NASDAQ Biotechnology position peaked at $5K in Q1 2016.
7 funds tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q2 2016.

Based on Creative Planning's 13F filing for Q2 2016, filed 12 Jul 2016.